|
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37808840 | Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. | | 2023 |
| 37874652 | Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. | | 2023 |
| 35180770 | Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics. | Cancer Research | 2022 |
| 35044810 | CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. | J Clin Oncol | 2022 |
| 35236825 | Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway. | Cell Death and Disease | 2022 |
| 34911787 | Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers. | Cancer Res | 2022 |
| 32865820 | Receiver operating characteristic curves and confidence bands for support vector machines. | Biometrics | 2021 |
| 33478572 | PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors. | Breast Cancer Research | 2021 |
| 33980863 | FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. | NPJ Breast Cancer | 2021 |
| 32573490 | FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. | J Clin Invest | 2020 |
| 32431541 | Long Noncoding RNA DLGAP1-AS1 Promotes the Aggressive Behavior of Gastric Cancer by Acting as a ceRNA for microRNA-628-5p and Raising Astrocyte Elevated Gene 1 Expression. | Cancer Management and Research | 2020 |
| 32023483 | Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. | Mol Cell | 2020 |
| 32690540 | Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer. | Cancer Discov | 2020 |
| 30845957 | I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms. | Genome Biol | 2019 |
| 31729379 | Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. | Nat Commun | 2019 |
| 31827079 | Genetic determinants of the molecular portraits of epithelial cancers. | Nat Commun | 2019 |
| 31822725 | Selective Effects of Thioridazine on Self-Renewal of Basal-Like Breast Cancer Cells. | Scientific Reports | 2019 |
| 29172851 | Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials. | Acta Oncol | 2018 |
| 30026228 | VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. | Science | 2018 |
| 30498031 | DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. | Proc Natl Acad Sci U S A | 2018 |
| 30497520 | Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. | Genome Medicine | 2018 |
| 30332649 | Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast. | Cell Rep | 2018 |
| 30089273 | Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland Development. | Cell Rep | 2018 |
| 30131338 | Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G arrest independent of DRD2. | Journal of Biological Chemistry | 2018 |
| 30037817 | Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. | Clin Cancer Res | 2018 |
| 28223411 | Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. | Science Signaling | 2017 |
| 28487385 | Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. | Cancer Res | 2017 |
| 28268222 | RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer. | Cell Physiol Biochem | 2017 |
| 27853751 | Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. | NPJ Breast Cancer | 2016 |
| 27144536 | MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. | Radiology | 2016 |
| 27216196 | Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers. | Cancer Research | 2016 |
| 26991655 | Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. | PLoS One | 2016 |
| 26430809 | Validation of the Lung Subtyping Panel in Multiple Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Lung Tumor Gene Expression Data Sets. | Arch Pathol Lab Med | 2016 |
| 27656679 | αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis. | NPJ Breast Cancer | 2015 |
| 25670223 | ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. | Sci Rep | 2015 |
| 25735774 | Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. | Cancer Discovery | 2015 |
| 25999348 | Gene expression in "young adult type" breast cancer: a retrospective analysis. | Oncotarget | 2015 |
| 26166574 | Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. | Cell Rep | 2015 |
| 26492917 | EglN2 associates with the NRF1-PGC1α complex and controls mitochondrial function in breast cancer. | EMBO Journal | 2015 |
| 26684470 | Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. | BMC Med | 2015 |
| 25239453 | BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development. | Cancer Research | 2014 |
| 23975155 | Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. | Clin Exp Metastasis | 2014 |
| 24435044 | Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. | J Clin Invest | 2014 |
| 24680597 | Obesity increases tumor aggressiveness in a genetically engineered mouse model of serous ovarian cancer. | Gynecologic Oncology | 2014 |
| 24990963 | Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. | Genes Dev | 2014 |
| 24527691 | Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. | Radiation Research | 2014 |
| 24520177 | Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. | Proc Natl Acad Sci U S A | 2014 |
| 25101563 | Predicting response and survival in chemotherapy-treated triple-negative breast cancer. | Br J Cancer | 2014 |
| 25151356 | An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. | Nat Genet | 2014 |